Review Article
A New Aurora in Anaplastic Thyroid Cancer Therapy
Table 1
Aurora kinase inhibitors in clinical trials.
| | | Inhibitor (company) commercial name | Clinical trial |
| | Pan-Aurora inhibitors | VX-680/MK-0457 (Vertex/Merck) Tozasertib | Phase II (terminated due to severe toxicity) | | PHA-739358 (Pfizer/Nerviano) Danusertib | Phase II | | PHA-680632 (Pfizer/Nerviano) | Phase II | | CYC-116 (Cyclacel) | Phase I | | SNS-314 (Sunesis) | Phase I | | R763 (Rigel) | Phase I | | AMG-900 (Amgen) | Phase I | | AT-9283 (Astex) | Phase II | | PF-03814375 (Pfizer) | Phase I | | GSK1070916 (GlaxoSmithKline) | Phase I |
| | Aurora-A inhibitors | MLN8237 (Millennium) | Phase II | | EMD-2076 (EntreMed) | Phase II | | MK-5108 (Vertex) | Phase I |
| | Aurora-B inhibitors | AZD1152 (AstraZeneca) | Phase II |
|
|
